Orthotopic liver transplantation (OLT) selection for patients with hepatocellular carcinoma (HCC) is a matter of debate. The Milan criteria (MC) have been largely adopted by the international community. The main aim of this study was to evaluate the survival rates and recurrence probabilities of a n
Criteria for diagnosing benign portal vein thrombosis in the assessment of patients with cirrhosis and hepatocellular carcinoma for liver transplantation
β Scribed by Fabio Piscaglia; Alice Gianstefani; Matteo Ravaioli; Rita Golfieri; Alberta Cappelli; Emanuela Giampalma; Elisabetta Sagrini; Grazia Imbriaco; Antonio Daniele Pinna; Luigi Bolondi
- Publisher
- John Wiley and Sons
- Year
- 2010
- Tongue
- English
- Weight
- 358 KB
- Volume
- 16
- Category
- Article
- ISSN
- 1527-6465
- DOI
- 10.1002/lt.22044
No coin nor oath required. For personal study only.
π SIMILAR VOLUMES
The purpose of this research was to study the efficacy and outcomes of transjugular intrahepatic shunt (TIPS) in end-stage liver disease (ESLD) patients with portal vein thrombosis (PVT) eligible for orthotopic liver transplant. Nine consecutive patients with PVT underwent TIPS as a nonemergent elec
In the present study, the results of living donor liver transplantation (LDLT) for 125 hepatocellular carcinoma (HCC) patients were analyzed to determine optimal criteria exceeding the Milan criteria (MC) but still with predictably good outcomes. On the basis of pretransplant imaging studies, 70 pat
Hepatocellular carcinoma (HCC) is a common indication for liver transplantation (LT). Currently, deceased donor LT is approved by the United Network for Organ Sharing for patients with HCC who meet the Milan criteria of a single tumor up to 5 cm or up to 3 tumors up to 3 cm as determined by imaging
The aim of this study was to identify high-risk patients Hepatocellular carcinoma (HCC) is a frequent comfor hepatocellular carcinoma (HCC). Among 151 patients plication of cirrhosis, and its prevalence increases as with histologically proven cirrhosis hospitalized from treatment of other complicati